March 21, 2024

The U.S. Food and Drug Administration (FDA) published a paper March 15, to update the public about intra-agency activities to oversee artificial intelligence (AI)-enabled healthcare technologies. The paper summarizes priorities shared across the biologics, drugs and medical devices domains of FDA jurisdiction.

Four general focus areas are discussed: fostering collaboration with stakeholders; developing appropriate regulatory approaches; promoting development of standards and best practices; and supporting research on performance evaluation. Moving forward, the FDA intends to evolve its own regulatory approaches with the continued progression of AI tools.

For more information about various American College of Radiology®(ACR®) AI-specific initiatives, visit the ACR Data Science Institute®. For more information about FDA oversight and digital health policy, contact Michael Peters, ACR Senior Government Affairs Director.


Related ACR News

  • ACR Urges CMS to Address Radiology Needs in 2026 HOPPS Rule

    ACR urges CMS to establish clear AI payment pathways in SaaS policy and calls for increased reimbursement for essential radiology services.

    Read more
  • ACR Champions Bill to Grow Physician Workforce

    ACR supports bipartisan bill to boost U.S. healthcare by recapturing unused visas for international doctors and nurses.

    Read more
  • HHS Issues Alert on Info Blocking Enforcement

    HHS issued an enforcement alert that info blocking rules still apply. ACR has radiology-focused guidance and FAQs available.

    Read more